Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Bee Venom Lab is a healthcare and cosmeceutical company specializing in the development of products derived from bee venom (apitoxin). The company focuses on the therapeutic application of melittin, a potent anti-inflammatory peptide found in bee venom, to treat joint and bone-related conditions. Their primary product line includes topical creams designed to alleviate symptoms of osteoarthritis, rheumatoid arthritis, and general musculoskeletal pain. In addition to pain management, the company produces professional-grade skincare formulations that utilize bee venom to promote skin elasticity and collagen synthesis. Bee Venom Lab operates as a direct-to-consumer brand, leveraging natural biological components for health and wellness applications. The company's research-driven approach aims to provide non-invasive alternatives to traditional pharmaceutical pain relief.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Bee Venom Lab.